Project Grant R21AI185534
Award Date
7/17/24
Completion Date
5/31/26
Dollars Obligated
$467K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $1,373,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to optimize the structural features of the anti-malarial compound ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. The research team, which includes experts in medicinal chemistry, malaria, molecular parasitology, biochemistry, structural biology,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $214,160 Project Grant (CFDA 93.855 Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to evaluate leveraging the Seasonal Malaria Chemoprevention (SMC) platform to deliver co-interventions that may augment the efficacy of SMC and reduce the incidence of malaria and malnutrition in children in the Sahel region of Africa. The two-year project aims to provide...
This federal Project Grant award, valued at $1,553,810.00 and granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research to develop a genomic surveillance approach for monitoring the emergence of artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The primary objectives are to: 1) Identify parasite genetic loci under selection over time following implementation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The funding supports the optimization of a next-generation antimalarial drug candidate, ELQ-596, to enable once-monthly oral prophylaxis in humans. Specifically, the research aims to enhance the structural features of ELQ-596 to improve its intrinsic anti-plasmodial activity,...
This federal Project Grant award of $791,864, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the molecular factors that control chromatin organization and gene regulation in the human malaria parasite Plasmodium falciparum. The key objectives of the project are to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,303,086 Project Grant (R01AI181383) to the University of Maryland, Baltimore to conduct a longitudinal cohort study on the epidemiological impact of malaria prevention interventions on school-age children in Ghana. The study aims to understand the effects of Seasonal Malaria Chemoprevention (SMC) and the RTS,S malaria vaccine on the burden of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,056 in funding to The Washington University to conduct research on heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify parasite proteins involved in maintaining heme levels and explore their potential as novel antimalarial drug targets. The award period runs from July...
This $924,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research at Tufts University School of Medicine to study mechanisms of erythrocyte adhesion in Plasmodium falciparum malaria, a leading cause of mortality worldwide. The key objectives are to: 1) Elucidate the mechanism of knob self-assembly on the surface of infected red blood cells, which...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...